Skip to main content
Premium Trial:

Request an Annual Quote

PathoFinder Obtains CE Mark for Two Multiplex SARS-CoV-2 MDx Tests

NEW YORK – Dutch molecular diagnostics developer PathoFinder has received CE IVD marking for two multiplex PCR tests for SARS-CoV-2 and other respiratory pathogens.

Specifically, the Maastricht-based firm obtained CE marking for the RespiFinder 2Smart kit for SARS-CoV-2 and Middle East respiratory syndrome-related coronavirus (MERS-CoV) testing, as well as for the RealAccurate Quadriplex (RAQ) Flu/COVID-19 PCR kit.

PathoFinder said that the RespiFinder 2Smart kit now detects 24 respiratory pathogens simultaneously using the company's proprietary 2SmartFinder technology. The SARS-CoV-2 N gene and MERS-CoV E gene were selected as targets to detect these additional viruses.

Meanwhile, the RAQ Flu/COVID-19 PCR kit detects and differentiates influenza A, influenza B, and SARS-CoV-2 (using the N gene and RdRp gene) from nasopharyngeal swabs.

PathoFinder received CE marking in April for its RealAccurate Quadruplex Corona-plus PCR kit for detecting SARS-CoV-2 from nasopharyngeal and oropharyngeal swabs, and in June for its RealAccurate Quadruplex SARS-CoV-2 PCR kit for detecting viral RNA by targeting the N and RdRp genes.

The Scan

Purnell Choppin Dies

Purnell Choppin, a virologist who led the Howard Hughes Medical Institute, has died at 91, according to the Washington Post.

Effectiveness May Decline, Data From Israel Suggests

The New York Times reports that new Israeli data suggests a decline in Pfizer-BioNTech SARS-CoV-2 vaccine effectiveness against Delta variant infection, though protection against severe disease remains high.

To See Future Risk

Slate looks into the use of polygenic risk scores in embryo screening.

PLOS Papers on Methicillin-Resistant Staphylococcus, Bone Marrow Smear Sequencing, More

In PLOS this week: genomic analysis of methicillin-resistant Staphylococcus pseudintermedius, archived bone marrow sequencing, and more.